RNS Number : 3501D

SalvaRx Group plc

09 October 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Exercise of Warrants

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that the Company has issued and allotted 60,563 ordinary shares of 2.5 pence each in the capital of the Company ("Ordinary Shares") at a price of 35.5 pence per share following an exercise of warrants.

The Company has made an application for the 60,563 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 12 October 2018. The 60,563 new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following Admission, the Company's total issued ordinary share capital will consist of 36,527,182 Ordinary Shares. The Company does not hold any shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.


 SalvaRx Group plc 
 Ian B. Walters, MD (Chief Executive)              Tel: +1 203 441 5451 
 Northland Capital Partners Limited           Tel: +44 (0) 20 3861 6625 
  Nominated Adviser and Broker 
 Matthew Johnson / Edward Hutton (Corporate 
 Vadim Alexandre (Corporate Broking) 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



(END) Dow Jones Newswires

October 09, 2018 02:00 ET (06:00 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Salvarx Charts.
Salvarx (LSE:SALV)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Salvarx Charts.